EXOZ
eXoZymes, Inc.
NASDAQ: EXOZ · HEALTHCARE · BIOTECHNOLOGY
$9.88
-1.76% today
Updated 2026-06-02
Market cap
$79.19M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.15
Dividend yield
—
52W range
$7 – $18
Volume
0.0M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C3.5
Quality
D3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-9.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -9.05 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.58M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $-700.00 |
| Net income | $-1.40M | $-2.04M | $-5.86M | $-9.16M | $-2.37M |
| EPS | — | — | — | — | $-1.15 |
| Free cash flow | $-1.44M | $-1.47M | $-8.90M | $-6.67M | $-1.58M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
eXoZymes, Inc. trades at $9.88. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -9.05, it sits in the distress. TTM revenue stands at $-700.00.
Frequently asked questions
What is eXoZymes, Inc.'s stock price?
eXoZymes, Inc. (EXOZ) trades at $9.88.
Is eXoZymes, Inc. overvalued?
eXoZymes, Inc. carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is eXoZymes, Inc.'s revenue?
eXoZymes, Inc.'s trailing twelve-month revenue is $-700.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
eXoZymes, Inc.'s Altman Z-Score is -9.05, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-185.80%
Beta—
50D MA$9.74
200D MA$11.28
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—